Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BSX logo

Boston Scientific Corp (BSX)BSX

Upturn stock ratingUpturn stock rating
Boston Scientific Corp
$85.1
Delayed price
Profit since last BUY6.94%
Regular Buy
upturn advisory
BUY since 45 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

10/24/2024: BSX (4-star) is a STRONG-BUY. BUY since 45 days. Profits (6.94%). Updated daily EoD!

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Regular Buy
Historic Profit: 41.83%
Upturn Advisory Performance Upturn Advisory Performance3
Avg. Invested days: 67
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 3
Last Close 10/24/2024
Type: Stock
Today’s Advisory: Regular Buy
Historic Profit: 41.83%
Avg. Invested days: 67
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 3
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/24/2024
Upturn Advisory Performance Upturn Advisory Performance3

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 133.13B USD
Price to earnings Ratio 74.65
1Y Target Price 97
Dividends yield (FY) -
Basic EPS (TTM) 1.21
Volume (30-day avg) 6049784
Beta 0.8
52 Weeks Range 53.93 - 91.08
Updated Date 11/19/2024
Company Size Large-Cap Stock
Market Capitalization 133.13B USD
Price to earnings Ratio 74.65
1Y Target Price 97
Dividends yield (FY) -
Basic EPS (TTM) 1.21
Volume (30-day avg) 6049784
Beta 0.8
52 Weeks Range 53.93 - 91.08
Updated Date 11/19/2024

Earnings Date

Report Date 2024-10-23
When BeforeMarket
Estimate 0.59
Actual 0.63
Report Date 2024-10-23
When BeforeMarket
Estimate 0.59
Actual 0.63

Profitability

Profit Margin 11.26%
Operating Margin (TTM) 17.06%

Management Effectiveness

Return on Assets (TTM) 4.9%
Return on Equity (TTM) 8.92%

Revenue by Products

Revenue by Products - Current and Previous Year

Revenue by Geography

Revenue by Geography - Current and Previous Year

Valuation

Trailing PE 74.65
Forward PE 32.26
Enterprise Value 141886836720
Price to Sales(TTM) 8.37
Enterprise Value to Revenue 8.92
Enterprise Value to EBITDA 38.08
Shares Outstanding 1473830016
Shares Floating 1469538647
Percent Insiders 0.18
Percent Institutions 92.47
Trailing PE 74.65
Forward PE 32.26
Enterprise Value 141886836720
Price to Sales(TTM) 8.37
Enterprise Value to Revenue 8.92
Enterprise Value to EBITDA 38.08
Shares Outstanding 1473830016
Shares Floating 1469538647
Percent Insiders 0.18
Percent Institutions 92.47

Analyst Ratings

Rating 4.45
Target Price 61.18
Buy 8
Strong Buy 20
Hold 5
Sell -
Strong Sell -
Rating 4.45
Target Price 61.18
Buy 8
Strong Buy 20
Hold 5
Sell -
Strong Sell -

AI Summarization

Boston Scientific Corp. (BSX): A Comprehensive Overview

Company Profile:

Detailed History and Background:

Boston Scientific Corporation (BSX) is a global medical device company founded in 1979. They started by developing and manufacturing angioplasty balloon catheters for the treatment of coronary artery disease. Over the years, BSX has expanded its portfolio through organic growth and acquisitions, becoming a leading player in various medical specialties, including:

  • Interventional Cardiology: Devices for treating heart disease, such as stents, balloons, and closure devices.
  • Cardiac Rhythm Management: Pacemakers, defibrillators, and cardiac resynchronization therapy devices.
  • MedSurg: Endoscopes, surgical staplers, hernia repair products, and more.
  • Neuromodulation: Spinal cord stimulation, deep brain stimulation, and other therapies for chronic pain and neurological disorders.
  • Oncology: Devices for minimally invasive cancer treatment.

Core Business Areas:

BSX operates through four main business segments:

  • Cardiovascular: Offers devices and solutions for treating heart disease, including coronary, peripheral, and structural heart conditions.
  • Rhythm Management: Provides pacemakers, defibrillators, and cardiac resynchronization therapies.
  • MedSurg: Focuses on devices and technologies for minimally invasive surgery, including endoscopy, hernia repair, and vascular access.
  • Neuromodulation: Develops and markets neuromodulation therapies for chronic pain, movement disorders, and other neurological conditions.

Leadership Team and Corporate Structure:

The company is led by CEO and President Mike Mahoney, CFO Jeff Capello, and a team of experienced executives. BSX operates in over 100 countries with a global workforce of approximately 40,000 employees.

Top Products and Market Share:

Top Products:

  • Stents: DES (Drug Eluting Stent) and BMS (Bare Metal Stent)
  • Mitral and Tricuspid Repair: TEER, TriClip, PASCAL
  • Peripheral Interventions: Embolization coils, drug-coated balloons
  • Pacemakers: Emblem, INCEPTA, ACUITY
  • Defibrillators: EMBLEM MRI S-ICD, INCEPTA MRI S-ICD
  • Endoscopy: PyloriX, SpyGlass DS
  • Neurostimulation: Spinal Cord Stimulator (SCS), Deep Brain Stimulation (DBS)

Market Share:

  • Global share of the coronary stent market: 20%
  • Global market leader in transcatheter mitral valve repair
  • US market leader in WATCHMAN left atrial appendage closure
  • Significant market share in various other segments including pacemakers, defibrillators, and endoscopy

Product Performance and Market Reception:

BSX's products are generally well-regarded by medical professionals and patients. The company has a strong track record of innovation and product development, consistently introducing new and improved technologies.

Total Addressable Market:

The global medical device market is estimated to be worth over $500 billion, with the cardiovascular device market alone valued at over $50 billion. BSX operates in several high-growth segments within this market, providing a substantial growth opportunity.

Financial Performance:

Recent Financial Statements:

  • Revenue: $13.41 billion (2022)
  • Net Income: $2.49 billion (2022)
  • Gross Profit Margin: 74% (2022)
  • Operating Margin: 30% (2022)
  • Earnings per Share (EPS): $4.17 (2022)

Year-over-Year Performance:

  • Revenue has grown at a CAGR of 8% over the past five years.
  • Net income has grown at a CAGR of 10% over the past five years.
  • EPS has grown at a CAGR of 12% over the past five years.

Cash Flow and Balance Sheet:

  • Strong cash flow generation, with operating cash flow of $3.3 billion in 2022.
  • Relatively low debt levels, with a debt-to-equity ratio of 0.5.

Dividends and Shareholder Returns:

Dividend History:

  • BSX has a history of paying dividends, with a current annual dividend yield of 0.66%.
  • The company has increased its dividend every year for the past 10 years.

Shareholder Returns:

  • Total shareholder returns over the past 5 years have been over 100%.

Growth Trajectory:

Historical Growth:

  • BSX has experienced consistent revenue and earnings growth over the past 5 to 10 years.

Future Growth Projections:

  • Analysts expect the company to continue growing at a moderate pace in the coming years.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Boston Scientific Corp

Exchange NYSE Headquaters Marlborough, MA, United States
IPO Launch date 1992-05-18 Chairman, President & CEO Mr. Michael F. Mahoney
Sector Healthcare Website https://www.bostonscientific.com
Industry Medical Devices Full time employees 48000
Headquaters Marlborough, MA, United States
Chairman, President & CEO Mr. Michael F. Mahoney
Website https://www.bostonscientific.com
Website https://www.bostonscientific.com
Full time employees 48000

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​